GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » Cash Flow from Discontinued Operations

Genocea Biosciences (Genocea Biosciences) Cash Flow from Discontinued Operations

: $0.00 Mil (TTM As of Mar. 2022)
View and export this data going back to 2014. Start your Free Trial

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Genocea Biosciences's cash flow from discontinued operations for the three months ended in Mar. 2022 was $0.00 Mil. It means Genocea Biosciences received $0.00 Mil from the sale of part of business quarterly. Genocea Biosciences's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Mar. 2022 was $0.00 Mil.


Genocea Biosciences Cash Flow from Discontinued Operations Historical Data

The historical data trend for Genocea Biosciences's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Discontinued Operations
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Cash Flow from Discontinued Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genocea Biosciences Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genocea Biosciences Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Genocea Biosciences (Genocea Biosciences) Business Description

Industry
Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Executives
Jacquelyn L Sumer officer: CHIEF LEGAL & COMPLIANCE OFF C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber director 2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall officer: CHIEF FINANCIAL OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell 10 percent owner
Stapleton Raymond D Jr officer: EVP PHARM SCI & MFG C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner officer: VP of Research C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815

Genocea Biosciences (Genocea Biosciences) Headlines

From GuruFocus

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

By GuruFocusNews GuruFocusNews 03-08-2022

Genocea Biosciences to Host Investor Webinar

By GuruFocusNews GuruFocusNews 04-04-2022

Genocea to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 01-05-2022

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 07-03-2022

Genocea to Present at Upcoming Scientific and Investor Conferences

By GlobeNewswire GlobeNewswire 09-08-2021

Genocea Biosciences Provides Corporate Update

By GuruFocusNews GuruFocusNews 01-04-2022

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

By GlobeNewswire GlobeNewswire 03-08-2022

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 06-03-2022

Genocea Provides Fourth Quarter 2021 Corporate Update

By GuruFocusNews GuruFocusNews 03-10-2022